In Wednesday's Analysts' Actions, we highlight downgrades for Twitter (TWTR) and Procter & Gamble (PG) as well as an upgrade for Eli Lilly (LLY).
Perrigo (PRGO) shares are rising after the company received its third unsolicited takeover from Mylan today with the company upping its offer to $35.6 billion.
Stocks endured a choppy day of trading Tuesday following a mixed bag of corporate earnings and as the Federal Reserve began their two-day meeting to discuss monetary policy.
Will the FDA bring together DMD experts for a single meeting to review both BioMarin's drisapersen and Sarepta's eteplirsen, or will two separate meetings be scheduled?
Drug maker Bristol Myers (BMY) posted earnings of $0.71 per share on Tuesday, beating analyst estimates.
Pfizer (PFE) shares are down after the company cut its full year financial forecast.
Pfizer's (PFE) new drugs pipeline gave their first quarter earnings a boost on Tuesday.
Bristol-Myers Squibb (BMY) shares are falling after the company beat analysts' earnings expectations but reported weak sales for one of its most important immunotherapy treatments.
Stocks were trading close to the flatline on Tuesday.
Pharmaceutical companies can be risky investments, yet some of these stocks do have upsides.
With Merck and Pfizer reporting earnings today, let's take a look at some of the best pharmaceutical companies TheStreet Quant Ratings says you should add to your portfolio right now.
Overall, Bristol sales in the March quarter were $4 billion, a 6% increase from one year ago and higher than consensus.
On an adjusted basis, Merck reported first quarter earnings per share of 85 cents, topping the Street consensus of 74 cents per share.
For Tuesday, April 28th we watch for earnings reports from Twitter (TWTR), GoPro (GPRO), Merck & Co (MRK), Pfizer (PFE), Ford (F), JetBlue (JBLU), and United Parcel Service (UPS).
The pharmaceutical giant said that Teva's offer was too low and that a new entity would create cultural and leadership problems.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV